Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
In pleading guilty, Mangione admitted to following UnitedHealth executive Brian Thompson and then shooting him.
The FDA approved a Bristol oral treatment for advanced multiple myeloma, marking the debut of a new class of medicine for the ...
Every parent experiences a unique mix of emotions when caring for a newborn baby. You’re filled with an overwhelming sense of ...
Methadone clinics don't have to be as rigid in how they dispense opioid addiction medicine. Some, though not all, are ...
The default to biomedical responses means that clinics and hospitals are increasingly absorbing the costs of social problems, ...
Noel T. Brewer and colleagues will soon decide whether the U.S. has maintained its elimination status. Here’s what they’re ...
How can we better reach out to people facing Medicaid renewal deadlines and support them through the paperwork requirements?
The White House says Trump’s recent executive order is aimed at restoring trust in vaccines. It will do the opposite, writes ...
Casey’s reporting examines the use of artificial intelligence by providers and insurers. The Federal Trade Commission is examining Epic Systems Corp., the nation’s largest vendor of electronic health ...
Meghana Keshavan covers biotech and contributes to The Readout newsletter. Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, ...
The FDA has approved Moderna’s influenza vaccine, the first licensed flu shot made using messenger RNA technology.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results